Pearl Steinzor

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

Heat-attributable CVD burden could reach 418 DALYs per 100,000 by 2050 under high-emissions scenarios, with low-income counties hit hardest.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.

Two posters presented at the EASL Congress 2026 highlight promising clinical and preclinical findings for AHB-137.

A turbulent regulatory environment is forcing covered entities to rethink how they manage 340B compliance.

Three hospital systems claim CVS Health secretly pocketed 340B savings meant for indigent care.

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

New scientific statement argues that heart failure with mildly reduced ejection fraction should no longer be treated as a “gray zone.”

A prospective registry study suggests cardiac MRI scar burden and biomarkers may refine prognostic assessment beyond current sudden cardiac death models.

An investigational coronary IVL catheter achieved high procedural success and favorable safety outcomes in patients with severely calcified CAD.

TrumpRx will include more than 600 generic medications; experts say the platform’s impact on high-cost specialty drug affordability may be limited.

New findings presented at ACC.26 highlight the potential of Lp(a)-targeted therapies for patients with ASVD and elevated Lp(a).

Exposure to adverse pregnancy outcomes may be associated with worse cardiovascular health and early arterial injury in young adulthood.

From rewriting drug approval standards to embedding AI in review workflows, former FDA commissioner Marty Makary, MD reshaped how evidence, speed, and access are balanced in US drug regulation.

New real-world evidence presented at PQA 2026 exposes the blind spots in how medication adherence is measured, monitored, and misunderstood.

Deborah Doroshow, MD, PhD, discusses lung cancer trial access, targeted therapy advances, and treatment gaps in part 2 of her interview.

RBM20 truncating variants are associated with a milder, lower-penetrance form of dilated cardiomyopathy compared with other pathogenic genetic drive.

Digitalis glycosides lowered worsening heart failure events in patients with HFmrEF and HFrEF, but no mortality benefit was observed.

In part 2, Deborah Doroshow, MD, PhD, discusses early clinical trial access, emerging lung cancer therapies, and barriers to equitable access.

Deborah Doroshow, MD, PhD, blends oncology and history of medicine to guide cancer care, emphasizing communication, trust, and health equity.

When added to maximally tolerated statin therapy, inclisiran was associated with significant reductions in MACE and hospitalizations among patients with ASCVD.

Here is a policy briefing for chief medical officers and managed care leaders on key pressure points about the Medicaid funding cuts.